INCR vs. ORIC, SVRA, IGMS, CDMO, CYRX, YMAB, SIGA, ALT, HRTX, and CMPS
Should you be buying InterCure stock or one of its competitors? The main competitors of InterCure include ORIC Pharmaceuticals (ORIC), Savara (SVRA), IGM Biosciences (IGMS), Avid Bioservices (CDMO), Cryoport (CYRX), Y-mAbs Therapeutics (YMAB), SIGA Technologies (SIGA), Altimmune (ALT), Heron Therapeutics (HRTX), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
InterCure (NASDAQ:INCR) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
In the previous week, ORIC Pharmaceuticals had 5 more articles in the media than InterCure. MarketBeat recorded 7 mentions for ORIC Pharmaceuticals and 2 mentions for InterCure. ORIC Pharmaceuticals' average media sentiment score of 0.83 beat InterCure's score of 0.43 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media.
InterCure has higher revenue and earnings than ORIC Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.
InterCure's return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.
InterCure has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
8.3% of InterCure shares are held by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
ORIC Pharmaceuticals has a consensus target price of $20.00, indicating a potential upside of 122.47%. Given ORIC Pharmaceuticals' higher possible upside, analysts plainly believe ORIC Pharmaceuticals is more favorable than InterCure.
ORIC Pharmaceuticals received 44 more outperform votes than InterCure when rated by MarketBeat users. However, 100.00% of users gave InterCure an outperform vote while only 66.20% of users gave ORIC Pharmaceuticals an outperform vote.
Summary
InterCure beats ORIC Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get InterCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for INCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InterCure Competitors List
Related Companies and Tools
